Theoretical and practical application of traditional and accelerated titration phase i clinical trial designs: The wayne state university experience

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 3, 2009, Pages 414-423

  Heath, Elisabeth I ^a   Lorusso, Patricia M ^a   Ivy, S Percy ^b   Rubinstein, Larry ^b   Christian, Michaele C ^b   Heilbrun, Lance K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Accelerated design; Phase I clinical trials; Traditional design

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 4 N ACETYLDINALINE; 5 FLUORO PYRIMIDINONE; 6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; CYTOTOXIC AGENT; FENRETINIDE; IXABEPILONE; NSC 374551; PYRAZINAMIDE; SR 233377; SR 271425; UNCLASSIFIED DRUG; XK 469; ANTINEOPLASTIC AGENT;

ACCELERATED TITRATION DESIGN; ADULT; ARTICLE; CANCER CENTER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG MEGADOSE; EXPERIENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THEORY; TRADITIONAL DESIGN; UNITED STATES; UNIVERSITY; ADOLESCENT; AGED; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; STANDARD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MICHIGAN; MIDDLE AGED; RESEARCH DESIGN; UNIVERSITIES; YOUNG ADULT;

EID: 67651055289     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400902800460     Document Type: Article

References (27)

1. Ahn, C. (1998). An evaluation of Phase I cancer clinical trial designs. Stat. Med. 17(14): 1537-1549.
2. Alousi, A. M., Boinpally, R., Wiegand, R., Parchment, R., Gadgeel, S., Heilbrun, L. K., Wozniak, A. J., DeLuca, P., LoRusso, P. M. (2007). A Phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest. New Drugs 25(2):147-154.
3. Cheung, Y. K., Chappell, R. (2000). Sequential designs for Phase I clinical trials with lateonset toxicities. Biometrics 56(4):1177-1182.
4. Collins, J. M., Zaharko, D. S., Dedrick, R. L., Chabner, B. A. (1986). Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treat. Rep. 70(1):73-80.
5. Edler, L. (1990). Statistical requirements of Phase I studies. Onkologie 13(2):90-95.
6. Gadgeel, S. M., Boinpally, R. R., Heilbrun, L. K., Wozniak, A., Jain, V., Redman, B., Zalupski, M., Wiegand, R., Parchment, R., LoRusso, P. M. (2003). A Phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a Phase I accelerated titration "2B" design. Invest. New Drugs 21(1):63-74.
7. Gadgeel, S. M., Wozniak, A., Boinpally, R. R., Wiegand, R., Heilbrun, L. K., Jain, V., Parchment, R., Colevas, D., Cohen, M. B., LoRusso, P. M. (2005). Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin. Cancer Res. 11(17):6233-6239.
8. Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., Workman, P. (1999). Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J. Natl. Cancer Inst. 91(15):1281-1287.
9. Goldsmith, M. A., Slavik, M., Carter, S. K. (1975). Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res. 35(5):1354-1364.
10. Goncalves, P. H., High, F., Juniewicz, P., Shackleton, G., Li, J., Boerner, S., LoRusso, P. M. (2008). Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies. Invest. New Drugs 26(4):347-354.
11. Horstmann, E., McCabe, M. S., Grochow, L., Yamamoto, S., Rubinstein, L., Budd, T., Shoemaker, D., Emanuel, E. J., Grady, C. (2005). Risks and benefits of Phase 1 oncology trials, 1991 through 2002. N. Engl. J. Med. 352(9):895-904.
12. Jasti, B. R. L. P., Parchment, R. E., Wozniak, A. J., Flaherty, L. E., Shields, A. F., Zalupski, M., Zwiebel, J. (2001). Phase I clinical trial of fenretinide (NSC374551) in advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 485.
13. Korn, E. L. (2004). Nontoxicity endpoints in Phase I trial designs for targeted, noncytotoxic agents. J. Natl. Cancer Inst. 96(13):977-978.
14. Koyfman, S. A., Agrawal, M., Garrett-Mayer, E., Krohmal, B., Wolf, E., Emanuel, E. J., Gross, C. P. (2007). Risks and benefits associated with novel Phase 1 oncology trial designs. Cancer 110(5):1115-1124.
15. Lin, Y., Shih, W. J. (2001). Statistical properties of the traditional algorithm-based designs for Phase I cancer clinical trials. Biostatistics 2(2):203-215.
16. LoRusso, P., Foster, B. J., Poplin, E., McCormick, J., Kraut, M., Flaherty, L., Heilbrun, L. K., Valdivieso, M., Baker, L. (1995). Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin. Cancer Res. 1(12):1487-1493.
17. LoRusso, P. M., Foster, B. J., Wozniak, A., Heilbrun, L. K., McCormick, J. I., Ruble, P. E., Graham, M. A., Purvis, J., Rake, J., Drozd, M., Lockwood, G. F., Corbett, T. H. (2000). Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin. Cancer Res. 6(8):3088-3094.
18. LoRusso, P. M., Prakash, S., Wozniak, A., Flaherty, L., Zalupski, M., Shields, A., Sands, H., Parchment, R., Jasti, B. (2002). Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU). Invest. New Drugs 20(1):63-71.
19. Mani, S., McDaid, H., Hamilton, A., Hochster, H., Cohen, M. B., Khabelle, D., Griffin, T., Lebwohl, D. E., Liebes, L., Muggia, F., Horwitz, S. B. (2004). Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. 10(4):1289-1298.
20. Parulekar, W. R., Eisenhauer, E. A. (2004). Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J. Natl. Cancer Inst. 96(13): 990-1907
21. Penta, J. S., Rosner, G. L., Trump, D. L. (1992). Choice of starting dose and escalation for Phase I studies of antitumor agents. Cancer Chemother. Pharmacol. 31(3):247-250.
22. Prakash, S., Foster, B. J., Meyer, M., Wozniak, A., Heilbrun, L. K., Flaherty, L., Zalupski, M., Radulovic, L., Valdivieso, M., LoRusso, P. M. (2001). Chronic oral administration of CI-994: A Phase 1 study. Invest. New Drugs 19(1):1-11.
23. Schneiderman, M. (1967). Mouse to man: Statistical problems in bringing a drug to clinical trial. In: Proceedings of the Fifth Berkely Symposium on Mathematical Statistics and Probability. Berkley, CA: University of California Press, pp. 885-1866
24. Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S. G., Collins, J., Christian, M. C. (1997). Accelerated titration designs for Phase I clinical trials in oncology. J. Natl. Cancer Inst. 89(15):1138-1147.
25. Spriggs, D. S. S., Bienvenu, B., Letrent, S., Lebwohl, D., Jones, S., Burris, H. (2001). Phase I First-in-Man study of the epothilone B analog BMS-247550 in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 428.
26. Supko, J. G., Eder, J. P. Jr., Ryan, D. P., Seiden, M. V., Lynch, T. J., Amrein, P. C., Kufe, D. W., Clark, J. W. (2003). Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin. Cancer Res. 9(14):5178-5186.
27. Wadler, S. L. E., Pilat, M., Malburg, L., Holloway, S., Matthews, N., Shackleton, G., Valdivieso, M., LoRusso, P. (2005). A Phase I trial of SR271425 given as a one hour infusion every 3 weeks in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 2030.